Trial of OS 2966 in patients with Ebola virus infections in West Africa

Trial Profile

Trial of OS 2966 in patients with Ebola virus infections in West Africa

Planning
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2015

At a glance

  • Drugs OS 2966 (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Sponsors OncoSynergy
  • Most Recent Events

    • 05 Jan 2015 New trial record
    • 16 Dec 2014 This study will be conducted in West Africa, according to a media release from CMC Biologics and OncoSynergy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top